Akeso Unveils Promising Results for Cadonilimab Combination Therapy at ELCC 2026 Akeso, Inc. presents compelling findings on cadonilimab's combination therapy for advanced NSCLC at ELCC 2026, marking a significant advancement in cancer treatment.

Akeso Unveils Promising Results for Cadonilimab Combination Therapy at ELCC 2026 #Hong_Kong #Akeso #Cadonilimab #NSCLC

Akeso Reports Transformative Year with Remarkable Sales Growth in 2025 Akeso, Inc. reported its impressive 2025 annual financial results, showcasing notable growth and advancements in oncology and immunotherapy sectors.

Akeso Reports Transformative Year with Remarkable Sales Growth in 2025 #China #Hong_Kong #Akeso #Cadonilimab #Ivonescimab

Cadonilimab Shows Promising Long-Term Survival Rates in R/M Cervical Cancer Patients Akeso, Inc. reports remarkable 24-month overall survival rates for cadonilimab-treated cervical cancer patients, reshaping treatment protocols.

Cadonilimab Shows Promising Long-Term Survival Rates in R/M Cervical Cancer Patients #China #Hong_Kong #Cancer_Treatment #Akeso #Cadonilimab

Innovative Collaboration in Cancer Treatment: INOVIO and Akeso Join Forces for Glioblastoma Therapy INOVIO Pharmaceuticals and Akeso team up to explore a promising therapy for glioblastoma, combining cutting-edge immunotherapy with advanced treatments to tackle this aggressive brain cancer.

Innovative Collaboration in Cancer Treatment: INOVIO and Akeso Join Forces for Glioblastoma Therapy #United_States #Akeso #Cadonilimab #INOVIO #Plymouth_Meeting

Cadonilimab Shows Superiority Over PD-1 Inhibitors for PD-L1-Low Gastric Cancer A recent study reveals that Cadonilimab significantly outperforms PD-1 inhibitors in treating advanced gastric cancer with PD-L1 low levels, enhancing survival rates.

Cadonilimab Shows Superiority Over PD-1 Inhibitors for PD-L1-Low Gastric Cancer #Hong_Kong #Cadonilimab #Advanced_Gastric_Cancer #PD-1_Inhibitors

Akeso's Cadonilimab Receives FDA Approval for Phase III Gastric Cancer Trial Akeso, Inc. announces FDA clearance to start a pivotal global trial evaluating cadonilimab for treatment of gastric cancer, comparing it with nivolumab.

Akeso's Cadonilimab Receives FDA Approval for Phase III Gastric Cancer Trial #Hong_Kong #gastric_cancer #Akeso #Cadonilimab

Promising Phase II Results for Cadonilimab in Neoadjuvant Therapy at ESMO Asia 2025 Cadonilimab shows significant promise as a neoadjuvant therapy in resectable gastric cancer, with impressive response rates presented at ESMO Asia 2025.

Promising Phase II Results for Cadonilimab in Neoadjuvant Therapy at ESMO Asia 2025 #Hong_Kong #ESMO_Asia #Akeso #Cadonilimab

Akeso Begins Phase I Trial for Personalized mRNA Vaccine Against Pancreatic Cancer Akeso, Inc. has initiated a Phase I clinical trial for its personalized mRNA vaccine, AK154, aimed at treating pancreatic cancer, both alone and with bispecific antibodies.

Akeso Begins Phase I Trial for Personalized mRNA Vaccine Against Pancreatic Cancer #Cadonilimab #Ivonescimab #AK154

Cadonilimab Shows Significant Overall Survival Benefits in Advanced Gastric Cancer Clinical Trial at ESMO 2025 At ESMO 2025, Akeso revealed compelling results from the COMPASSION-15 study highlighting cadonilimab’s efficacy for advanced gastric cancer treatment.

Cadonilimab Shows Significant Overall Survival Benefits in Advanced Gastric Cancer Clinical Trial at ESMO 2025 #Hong_Kong #gastric_cancer #Akeso #Cadonilimab

Akeso Inc. Presents Pioneering Ivonescimab and Cadonilimab Research at ESMO 2025 Congress Akeso Inc. is set to showcase groundbreaking results for ivonescimab and cadonilimab at the ESMO 2025 Congress, marking crucial advancements in cancer therapy.

Akeso Inc. Presents Pioneering Ivonescimab and Cadonilimab Research at ESMO 2025 Congress #Hong_Kong #Cadonilimab #Ivonescimab #Akeso_Inc.

Akeso Doses First Patient in Groundbreaking Trial for Liver Cancer Treatment Akeso, Inc. announces its first patient has been dosed in a pivotal global trial for a new liver cancer treatment, marking a key advancement in cancer therapy.

Akeso Doses First Patient in Groundbreaking Trial for Liver Cancer Treatment #None #Akeso #Cadonilimab #HCC

Promising Results of Cadonilimab and Pulocimab in Treating Resistance in Lung Cancer Akeso Inc. presents encouraging clinical study results for cadonilimab and pulocimab in treating IO-resistant non-small cell lung cancer, showcasing new hope for patients.

Promising Results of Cadonilimab and Pulocimab in Treating Resistance in Lung Cancer #Hong_Kong #Akeso #Cadonilimab #Pulocimab

Akeso Reports Record Sales and Major Oncology Advances in 2025 Interim Results Akeso, Inc. has shared its 2025 interim results, revealing spectacular commercial sales growth and significant breakthroughs in oncology and autoimmune therapies.

Akeso Reports Record Sales and Major Oncology Advances in 2025 Interim Results #Akeso #Cadonilimab #Ivonescimab

First Patient Enters Phase III Trial for Innovative Cancer Treatment Cadonilimab Akeso's cadonilimab, a promising treatment for gastric cancer, has initiated a Phase III trial aiming to improve patient outcomes significantly.

First Patient Enters Phase III Trial for Innovative Cancer Treatment Cadonilimab #China #Hong_Kong #Akeso #Cadonilimab #G/GEJ_Adenocarcinoma

Akeso to Launch Global Clinical Trial Evaluating Cadonilimab for Liver Cancer Akeso is set to begin a global Phase II trial for Cadonilimab, targeting treatment-resistant liver cancer, aiming to offer new hope for patients.

Akeso to Launch Global Clinical Trial Evaluating Cadonilimab for Liver Cancer #Hong_Kong #liver_cancer #Akeso #Cadonilimab

Exploring Cadonilimab's Impact in First-Line Therapy for Advanced Cervical Cancer at ASCO 2025 Akeso, Inc. revealed transformative findings on Cadonilimab's efficacy as a first-line treatment for advanced cervical cancer at ASCO 2025, addressing critical patient care.

Exploring Cadonilimab's Impact in First-Line Therapy for Advanced Cervical Cancer at ASCO 2025 #None #Akeso #Cadonilimab #Cervical_Cancer

Akeso's Cadonilimab Secures NMPA Approval for Cervical Cancer Treatment Akeso's cadonilimab receives NMPA approval as a groundbreaking treatment for cervical cancer, enhancing patient options in China. This marks the drug's third approved indication, highlighting Akeso's innovative efforts in oncology.

Akeso's Cadonilimab Secures NMPA Approval for Cervical Cancer Treatment #China #Hong_Kong #Akeso #Cadonilimab #Cervical_Cancer

Akeso's 2024 Annual Report: Innovations in Bispecific Antibodies and Global Market Expansion Akeso highlights its breakthroughs in bispecific antibodies, global competitive strength, and comprehensive oncology strategies in 2024.

Akeso's 2024 Annual Report: Innovations in Bispecific Antibodies and Global Market Expansion #Hong_Kong #Akeso #Cadonilimab #Ivonescimab

Akeso Presents Breakthrough Data on Cadonilimab for Cervical Cancer at 2025 SGO Meeting At the 2025 SGO Meeting, Akeso showcased impressive results from their study on cadonilimab, a promising treatment for advanced cervical cancer.

Akeso Presents Breakthrough Data on Cadonilimab for Cervical Cancer at 2025 SGO Meeting #China #Hong_Kong #Cadonilimab #Cervical_Cancer #Akeso_Inc

Akeso Completes Patient Enrollment for Cadonilimab Phase III Clinical Trial in Hepatocellular Carcinoma Treatment Akeso, Inc. has announced the completion of patient enrollment for its Phase III trial of Cadonilimab, targeting high-risk recurrent hepatocellular carcinoma after surgery. This milestone marks a step forward in HCC treatments.

Akeso Completes Patient Enrollment for Cadonilimab Phase III Clinical Trial in Hepatocellular Carcinoma Treatment #China #Hong_Kong #Akeso #Cadonilimab #HCC

Akeso Begins Phase 3 Trial for Innovative Cadonilimab in Lung Cancer Therapy Akeso has enrolled its first patient in a Phase 3 trial for cadonilimab, targeting lung cancer consolidation therapy after chemoradiotherapy. Explore the potential of this innovative drug.

Akeso Begins Phase 3 Trial for Innovative Cadonilimab in Lung Cancer Therapy #China #Hong_Kong #Akeso #Cadonilimab #NSCLC

Promising Phase III Results for Cadonilimab in Advanced Gastric Cancer Published in Nature Medicine Akeso, Inc. has announced groundbreaking Phase III results for cadonilimab's first-line treatment of advanced gastric cancer, published in Nature Medicine. This study underlines its improved efficacy and survival rates.

Promising Phase III Results for Cadonilimab in Advanced Gastric Cancer Published in Nature Medicine #Hong_Kong #gastric_cancer #Akeso #Cadonilimab

Akeso Unveils Promising Results for Cadonilimab in Fighting NSCLC at ACLC 2024 Latest findings from Akeso's cadonilimab showcase its potential as an effective treatment for PD-(L)1 resistant non-small cell lung cancer patients at the ACLC 2024.

Akeso Unveils Promising Results for Cadonilimab in Fighting NSCLC at ACLC 2024 #Hong_Kong #Akeso #Cadonilimab #NSCLC

Akeso's Cadonilimab and Ivonescimab Selected for China's National Reimbursement Drug List Akeso announces its pioneering bispecific antibodies Cadonilimab and Ivonescimab have been added to China's National Reimbursement Drug List, effective January 1, 2025, enhancing patient access to innovative treatments.

Akeso's Cadonilimab and Ivonescimab Selected for China's National Reimbursement Drug List #China #Hong_Kong #Akeso #Cadonilimab #Ivonescimab